This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ferreira, C Articles by Fiuáza, T Search for Related Content PubMed PubMed Citation Articles by Ferreira, C Articles by Fiuáza, T Social Bookmarking                         What's this?

Plasma homovanillic acid and prolactin in systemic lupus erythematosus

Departments of Medicine IV of the Hospital Santa Maria, Lisboa, Portugal

M Paes

Departments of Pharmacology of the Hospital Santa Maria, Lisboa, Portugal

A Gouveia

Departments of Biomathematic Laboratory, of the Hospital Santa Maria, Lisboa, Portugal

E Ferreira

F Pádua

T Fiuáza

Departments of Medicine IV of the Hospital Santa Maria, Lisboa, Portugal

Prolactin (PRL) is an important immunoregulator and might have a role in the pathogenesis of systemic lupus erythematosus (SLE). The regulation of pituitary prolactin secretion is complex and involves a negative feedback process in the hypothalamus, in which dopamine plays the principal role. However, the main source of serum prolactin in lupus patients is still not clearly established. Since homovanillic acid (HVA), the principal metabolite of dopamine (DA), is removed from the brain into the blood, it would indirectly reflect DA metabolism. It is assumed that the turnover of a neurotransmitter can be determined through an analysis of its metabolites. The objective of this study was to analyse plasma samples from SLE patients to see if there were any alterations in neurally functioning DA through its principal metabolite, HVA. We also measured the levels of PRL and compared HVA and PRL with the clinical activity of the disease. Twenty-four SLE patients and fifteen healthy controls were studied. The investigation was done over a period of 3 months.

The results of this study show significantly low levels of HVA in lupus patients compared to controls (P < 0.0001). This corresponds to a decrease in dopamine turnover. Hyperprolactinemia was observed in nine patients, and the average level of prolactin in lupus patients was higher than in healthy controls (P < 0.001). For the duration of the study, a significant percentage of variation was observed in the levels of HVA in the clinically active patients (P < 0.05) compared to inactive patients. When PRL was compared in these groups, throughout the study, no signifcant percentage of variation was observed. The relationship between HVA and PRL in healthy controls was r = 0.47, P=0.08, and in patients was r = 0.04, P = 0.84. It is suggested that there is a probable association between plasma levels of HVA and PRL in the healthy controls and not in the SLE patients.

Key Words: prolactin • systemic lupus erythematosus • homovanillic acid

Lupus, Vol. 7, No. 6, 392-397 (1998)
DOI: 10.1191/096120398678920299


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I Mendez, J Alcocer-Varela, A Parra, A Lava-Zavala, D A de la Cruz, D Alarcon-Segovia, and F Larrea Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin Lupus, January 1, 2004; 13(1): 45 - 53. [Abstract] [PDF]

				S E Walker and L.-y. Yu-Lee Overview: prolactin and autoimmunity Lupus, October 1, 2001; 10(10): 659 - 659. [PDF]

				L J Jara, O Vera-Lastra, J M Miranda, M Alcala, and J Alvarez-Nemegyci Prolactin in human systemic lupus erythematosus Lupus, October 1, 2001; 10(10): 748 - 756. [Abstract] [PDF]

				S E Walker, D Miller, D L Hill, and G R Komatireddy Prolactin, a pituitary hormone that modifies immune responses: Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico Lupus, July 1, 1998; 7(6): 371 - 375. [PDF]